A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

NCT05653219 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

152

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Immune Thrombocytopenia

Interventions

BIOLOGICAL: Ianalumab
DRUG: Eltrombopag
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals